BR112021002730A2 - proteínas bispecíficas engenheiradas - Google Patents
proteínas bispecíficas engenheiradas Download PDFInfo
- Publication number
- BR112021002730A2 BR112021002730A2 BR112021002730-0A BR112021002730A BR112021002730A2 BR 112021002730 A2 BR112021002730 A2 BR 112021002730A2 BR 112021002730 A BR112021002730 A BR 112021002730A BR 112021002730 A2 BR112021002730 A2 BR 112021002730A2
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptide
- seq
- protein according
- antigen
- linker
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70582—CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765095P | 2018-08-16 | 2018-08-16 | |
| US62/765,095 | 2018-08-16 | ||
| PCT/US2019/046705 WO2020037150A2 (en) | 2018-08-16 | 2019-08-15 | Engineered bispecific proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021002730A2 true BR112021002730A2 (pt) | 2021-08-10 |
Family
ID=69525976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021002730-0A BR112021002730A2 (pt) | 2018-08-16 | 2019-08-15 | proteínas bispecíficas engenheiradas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220017634A1 (https=) |
| EP (1) | EP3850007A4 (https=) |
| JP (1) | JP7397063B2 (https=) |
| KR (1) | KR20210064199A (https=) |
| CN (1) | CN112839955A (https=) |
| AU (1) | AU2019320803A1 (https=) |
| BR (1) | BR112021002730A2 (https=) |
| CA (1) | CA3109763A1 (https=) |
| EA (1) | EA202190542A1 (https=) |
| IL (1) | IL280882A (https=) |
| MA (1) | MA53616A (https=) |
| MX (1) | MX2021001711A (https=) |
| SG (1) | SG11202101273VA (https=) |
| WO (1) | WO2020037150A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| PH12022551598A1 (en) | 2019-12-23 | 2023-11-20 | Denali Therapeutics Inc | Progranulin variants |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| EP4229192A1 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| WO2023038803A2 (en) * | 2021-08-25 | 2023-03-16 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| WO2023085779A1 (ko) * | 2021-11-09 | 2023-05-19 | 한양대학교 산학협력단 | Fc 변이체를 포함하는 이종이합체 및 이의 제조방법 |
| JP2025503437A (ja) * | 2021-12-17 | 2025-02-04 | デナリ セラピューティクス インコーポレイテッド | ポリペプチド操作、ライブラリー、ならびに操作されたｃｄ９８重鎖及びトランスフェリン受容体結合ポリペプチド |
| US12011489B2 (en) | 2022-03-30 | 2024-06-18 | Christopher Key | Compositions and methods for treating inflammatory disease |
| KR20250058123A (ko) | 2022-07-29 | 2025-04-29 | 리제너론 파마슈티칼스 인코포레이티드 | 항-TfR:페이로드 융합 및 이의 사용 방법 |
| CA3263388A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | VIRAL PARTICLES RETRIBUTED TO TRANSFERRIN RECEPTOR 1 |
| CN120659627A (zh) | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| CN118221803A (zh) * | 2022-12-19 | 2024-06-21 | 深圳科兴药业有限公司 | 异源二聚体Fc融合蛋白及其用途 |
| IL326018A (en) | 2023-07-28 | 2026-03-01 | Regeneron Pharma | Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease |
| US20250049896A1 (en) | 2023-07-28 | 2025-02-13 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1697520A2 (en) * | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| SG11201404751UA (en) * | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| EP3594240B1 (en) * | 2013-05-20 | 2023-12-06 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| CA2944402A1 (en) * | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| HUE057952T2 (hu) * | 2015-06-24 | 2022-06-28 | Hoffmann La Roche | Anti-transzferrin receptor antitestek testreszabott affinitással |
| CN107531788B (zh) * | 2015-06-24 | 2022-06-21 | 豪夫迈·罗氏有限公司 | 对her2和血脑屏障受体特异性的三特异性抗体及使用方法 |
| EA039366B1 (ru) * | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| CA2998174A1 (en) * | 2015-09-15 | 2017-03-23 | Amgen Inc. | Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof |
| CN110506055A (zh) * | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| SG11201907422RA (en) * | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| US10457717B2 (en) * | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| WO2018237338A1 (en) * | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| WO2019055841A1 (en) * | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| CR20200129A (es) * | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| WO2019094576A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Bace-tau bispecific antibodies |
| WO2019094608A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| TW201934573A (zh) * | 2018-01-10 | 2019-09-01 | 美商戴納立製藥公司 | 轉鐵蛋白受體結合性多肽及其用途 |
| WO2019246071A1 (en) * | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
-
2019
- 2019-08-15 WO PCT/US2019/046705 patent/WO2020037150A2/en not_active Ceased
- 2019-08-15 JP JP2021507761A patent/JP7397063B2/ja active Active
- 2019-08-15 BR BR112021002730-0A patent/BR112021002730A2/pt not_active IP Right Cessation
- 2019-08-15 KR KR1020217007602A patent/KR20210064199A/ko not_active Withdrawn
- 2019-08-15 MX MX2021001711A patent/MX2021001711A/es unknown
- 2019-08-15 MA MA053616A patent/MA53616A/fr unknown
- 2019-08-15 CA CA3109763A patent/CA3109763A1/en active Pending
- 2019-08-15 AU AU2019320803A patent/AU2019320803A1/en not_active Abandoned
- 2019-08-15 CN CN201980066244.0A patent/CN112839955A/zh active Pending
- 2019-08-15 EA EA202190542A patent/EA202190542A1/ru unknown
- 2019-08-15 SG SG11202101273VA patent/SG11202101273VA/en unknown
- 2019-08-15 EP EP19849330.6A patent/EP3850007A4/en not_active Withdrawn
-
2021
- 2021-02-11 US US17/174,231 patent/US20220017634A1/en not_active Abandoned
- 2021-02-15 IL IL280882A patent/IL280882A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112839955A (zh) | 2021-05-25 |
| SG11202101273VA (en) | 2021-03-30 |
| MX2021001711A (es) | 2021-05-27 |
| CA3109763A1 (en) | 2020-02-20 |
| WO2020037150A2 (en) | 2020-02-20 |
| US20220017634A1 (en) | 2022-01-20 |
| EA202190542A1 (ru) | 2021-09-07 |
| EP3850007A4 (en) | 2022-08-10 |
| IL280882A (en) | 2021-04-29 |
| MA53616A (fr) | 2022-05-04 |
| JP2021533779A (ja) | 2021-12-09 |
| AU2019320803A1 (en) | 2021-03-11 |
| EP3850007A2 (en) | 2021-07-21 |
| WO2020037150A3 (en) | 2020-10-15 |
| JP7397063B2 (ja) | 2023-12-12 |
| KR20210064199A (ko) | 2021-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7397063B2 (ja) | 操作された二重特異性タンパク質 | |
| US11370832B2 (en) | Anti-Tau antibodies and methods of use thereof | |
| JP2025083406A (ja) | 操作されたトランスフェリン受容体結合ポリペプチド | |
| ES2956062T3 (es) | Polipéptidos de unión al receptor de transferrina diseñados por ingeniería | |
| US11773185B2 (en) | Anti-BACE1 antibodies and methods of use thereof | |
| CN111787951A (zh) | 影响IgM血清半衰期的IgM Fc和J链突变 | |
| BR112021002953A2 (pt) | polipeptídeos anti-her2 e métodos de uso dos mesmos | |
| CN107787329B (zh) | 以高亲和力、亲和性及特异性结合转化生长因子-β1的经修饰的IgG抗体 | |
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| WO2023114510A2 (en) | Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides | |
| KR102884943B1 (ko) | 개선된 항-flt3 항원 결합 단백질 | |
| US20230074436A1 (en) | Anti-alpha-synuclein antibodies and methods of use thereof | |
| WO2019094576A1 (en) | Bace-tau bispecific antibodies | |
| US20240392035A1 (en) | Engineered anti-her2 bispecific proteins | |
| HK40115088A (zh) | 多肽工程化、文库和工程化cd98重链以及转铁蛋白受体结合多肽 | |
| HK40084724A (en) | Engineered anti-her2 bispecific proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2788 DE 11-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |